Phase 1 Study of ONT-380, a HER2 Inhibitor, in Patients With HER2-Positive Advanced Solid Tumors, with an Expansion Cohort in HER2-Positive Metastatic Breast Cancer (MBC)

ONT-380 had lower incidence and severity of diarrhea and rash than that typically associated with current dual HER2/EGFR inhibitors and showed notable anti-tumor activity in heavily pretreated HER2-positive MBC patients.

 Clin Cancer Res

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.